|
Session 174-Poster Abstracts
Response to Protective Vaccines in Children
Friday, 2-4 pm; Poster Hall |
880
 |
Persistence of Protective Antibody to Hepatitis B, Japanese Encephalitis, Measles, Mumps, and Rubella up to 3 Years after Revaccination in HIV-infected Children with Immune Recovery a
Linda Aurpibul*1, T Sujaridruk2, M Lao-araya2, T Puthanakit1, T Sirisanthana1, and V Sirisanthana1
1Res Inst for Hlth Sci, Chiang Mai Univ, Thailand and 2Faculty of Med, Chiang Mai Univ, Thailand |
881
|
28- and 72-week Immunogenicity of 1 Dose vs 2 Doses of Quadrivalent Meningococcal Conjugate Vaccine in HIV-infected Youth
Jorge Lujan-Zilbermann*1, P Williams2, G Siberry3, M Warshaw2, S Spector4, M Decker5, A Manzella6, J Read3, P Jean-Philippe7, S Nachman8, and IMPAACT P-1065 Study Group
1Univ of South Florida Coll of Med, Tampa, US; 2Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, US; 3Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 4Univ of California, San Diego, La Jolla, US; 5Sanofi Pasteur Inc, Swiftwater, PA, US; 6Frontier Sci and Tech Res Fndn, Amherst, NY, US; 7Henry M Jackson Fndn for the Advancement of Military Med, NIAID, NIH, Bethesda, MD, US; and 8State Univ of New York at Stony Brook, US |
| 882 |
Anti-Influenza Serum and Mucosal Antibody Responses after Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-infected Children
Adriana Weinberg*1, L-Y Song2, M Allende3, T Fenton2, J Patterson-Bartlett1, S Nachman4, P Defechereux5, D Wara5, J Read6, M Levin1, and IMPAACT P1057 Team
1Univ of Colorado Denver, Aurora, US; 2Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, US; 3MedImmune, Inc, Gaithersburg, MD, US; 4State Univ of New York at Stony Brook, US; 5Univ of California, San Francisco, US; and 6Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US |
|
